Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mark S. Cragg"'
Autor:
Jane E. Willoughby, Ivo Tews, Ruth R. French, Chris Orr, Ali Roghanian, Anne White, Stephen A. Beers, Martin J. Glennie, Xiaojie Yu, Mark S. Cragg, Hayden Fisher, Aymen Al-Shamkhani, Osman Dadas
Publikováno v:
Blood Cancer Discovery. 1:IA03-IA03
Agonistic antibodies directed to immunostimulatory receptors are a currently untapped source for immunotherapy. Whereas checkpoint blockers have translated into the clinic, the rules for agonistic antibodies have been more difficult to discern and th
Autor:
Michael Crump, Sarit Assouline, Nicole Thomas, Neil R Michaud, Marco A. Marra, Christopher Rushton, Laura K. Hilton, Kevin Bushell, Ryan N Rys, Kirstie L. S. Cleary, Ryan D. Morin, Sarah E. Arthur, Koren K. Mann, Aixiang Jiang, Michael D. Jain, John Kuruvilla, Mark S. Cragg, Nathalie A. Johnson, Krysta M. Coyle, Matthew C. Cheung, Christian Steidl, Lois E. Shepherd, Miguel Alcaide, David Scott
Publikováno v:
Blood Cancer Discovery. 1:IA42-IA42
A significant proportion of diffuse large B-cell lymphoma (DLBCL) patients treated with immunochemotherapy containing rituximab (R-CHOP) exhibit either primary or acquired treatment resistance. The advancement of therapeutics in the relapse setting h
Autor:
Stephen A. Beers, Andrea Knapp, Mark S. Cragg, Matthew J. Carter, Kathleen N. Potter, Laura K Hilton, Ryan D. Morin, Maurizio Martelli, Malgorzata Nowicka, Pedro Farinha, Cathy Burton, Mikkel Z. Oestergaard, Laurie H. Sehn, Jonathan C. Strefford, Umberto Vitolo, Chern Lee, Graham W. Slack, Chantal E. Hargreaves, Margaret Ashton-Key, Christian Klein, Matthew J. J. Rose-Zerilli, Christopher R. Bolen, Wolfram Klapper, Farheen Mir, Marek Trneny, Russell Foxall, David W. Scott
Publikováno v:
Blood Cancer Discovery. 1:PO-26
Background: The anti-CD20 monoclonal antibody (mAb), obinutuzumab (G), has shown improved outcomes versus rituximab (R) in indolent lymphomas; however, no improvement was seen in diffuse large B-cell lymphoma (DLBCL), and the molecular basis is uncle